Our Blog

Immutep to present positive results in melanoma trial

17 May 2019 – Biotech company Immutep (ASX:IMM) today announces more mature data relating to Part B of its ongoing phase I TACTImel clinical study of the Company’s lead product candidate, efti-lagimod alpha (“efti” or “IMP321”) in patients with melanoma.


Source: Finance News Network

Share this post